The importance of developing therapies targeting the biological spectrum of metastatic disease
Andries Zijlstra(Vanderbilt University), Julio A. Aguirre‐Ghiso(Albert Einstein College of Medicine), John T. Price(The University of Melbourne), Thomas R. Cox(Garvan Institute of Medical Research), Dihua Yu(The University of Texas MD Anderson Cancer Center), Ariana von Lersner(Vanderbilt University), Yibin Kang(Rutgers, The State University of New Jersey), Lucia Borrello(Albert Einstein College of Medicine), Barbara Fingleton(Vanderbilt University), Madeleine J. Oudin(Tufts University), Yukio Kato(Kanazawa University), Ulrike Stein(Max Delbrück Center), Erik Sahai(The Francis Crick Institute), Alana L. Welm(Huntsman Cancer Institute)
Cited by 13
Related Papers
A framework for advancing our understanding of cancer-associated fibroblasts
|Nature reviews. Cancer|2020|3.7k
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET
|Nature Medicine|2012|3.7k
Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations
|Science|2002|2.7k
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
|Cancer Cell|2004|1.9k
Matrix Metalloproteinases: Biologic Activity and Clinical Implications
|Journal of Clinical Oncology|2000|1.6k